Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Income from Continuing Operations (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Income from Continuing Operations for 16 consecutive years, with 44784000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 244.06% to 44784000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 124453000.0 through Dec 2025, up 3186.63% year-over-year, with the annual reading at 124453000.0 for FY2025, 3186.63% up from the prior year.
  • Income from Continuing Operations hit 44784000.0 in Q4 2025 for Ligand Pharmaceuticals, down from 117273000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 117273000.0 in Q3 2025 to a low of 51911000.0 in Q2 2024.
  • Historically, Income from Continuing Operations has averaged 12268700.0 across 5 years, with a median of 11122000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 2366.86% in 2024 and later soared 1735.15% in 2025.
  • Year by year, Income from Continuing Operations stood at 13799000.0 in 2021, then plummeted by 205.33% to 14534000.0 in 2022, then soared by 225.14% to 18188000.0 in 2023, then tumbled by 270.93% to 31088000.0 in 2024, then surged by 244.06% to 44784000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for LGNDZ at 44784000.0 in Q4 2025, 117273000.0 in Q3 2025, and 4847000.0 in Q2 2025.